Group I and III metabotropic glutamate receptors agonists reverse 1-methyl-4-phenylpyridinium-induced glutamate uptake inhibition in C6 glioma cells

Abstract

Abstract: AIM: To study the effect of group II and Ill metabotropic glutamate receptors (mGluRs) agonistson 1-methyl-4-phenylpyridinium (MPP⁺) induced gluta-mate uptake inhibition in C6 glioma cell.METHODS: The glutamate uptake into astrocytes was measured by using radio-ligand binding assay method.RESULTS: It was shown that Group II mGluRs agonist (2 ‘S, 2'R, 3'R)-2-(2 ‘ 3'-dicarboxycyclopropyl glycine (DCG-IV(100μmol·L^-1) and Group II mGluRs agonist L (+)-2amino-4-phosphonobutyric acid (L-AP4) (100μmol·L^-1) significantly reversed Mpp⁺-induced gluta-mate uptake inhibition. Furthermore, the enhancementeffects of DCG-IV and L-AP4 were blocked by their re-spective antagonists, (RS)^-1-Amino-5-phosphonoinan^-1carboxylic acid (APICA and (RS)-α-methylserine-Ophosphate (MSOP).CONCLUSION: Group II and Ill mGluRs agonists produce neuroprotective effects byenhancing the activity of glutamate transporters.

Key words: metabotropic glutamate receptors, MPP⁺, C6 glioma cells, glutamate uptake

CLC Number:

R730.1

WANG Fang, YAO Hong-hong, HU Gang. Group I and III metabotropic glutamate receptors agonists reverse 1-methyl-4-phenylpyridinium-induced glutamate uptake inhibition in C6 glioma cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(10): 1096-1099.

References

1 Wichman T, Delong MR. Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder [J]. Ann N Y Acad Sci. 2003: 991: 199-213
2 Frandsen A, Schousboe A. AMPA receptor-mediated neurotoxicity: role of Ca²⁺ and desensitization [J]. Neurochem Res 2003: 28: 1495-9
3 Plaitakis A, Shashidharan P. Glutamate transport and tabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease [J].J Neurol,. J Neurol1125-35
4 Perier C, Marin C, Bonastre M. AMPA receptor antagonist LY293558 reverses preproenkephalin MRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopal[J]. Eur J Neurosci, 2002: 16: 2236-40
5 Wolfarth S, Konieczny J, Lorenc-koci E. The role of metabo-tropic glutamate receptor (MGLUR) ligands in parkinsonian muscle rigidity [J]. Amino Acids, 2000; 19: 95-101
6 Vezina P, Kim JH. Metabotropic glutamate receptors and the generation of locomotor activity: interactions with midbrain o-paminel[J]. Neurosci Biobehav Rev, 1999: 23: 577-89
7 Bruton RK, Ge J, Banes NM. Group Imglu receptor modulation of dopamine release in the rat striatum [J]. Eur J Pharmacol. 1999: 369: 175-8
8 Cai Z. Xiao F, Fratkin I D, Rhodes PG.Protection of neonatalI brain from hypoxic-ischemic injury by LY379268. a Group II metabotropic glutamate receptor agonist [J]. Neuroreport, 1999;10: 3927-3
9 Maiese K, Vincent A, Lin SH. Shaw T.Group I and group Imetabotropic glutamate receptor subtypes provide enhanced neuro protection [J]. J Neurosci Res, 2000; 62: 257
10 王芳,姚红红,胡冈. II,III组亲代谢型谷氨酸受体激动剂逆转1–甲基–4苯基口吡啶离子抑制星形胶质细胞摄取谷氨酸[J].中国临床药理学与治疗学,2004;9:485-9
11 Yao HH, Ding JH, Zhou F, Wang F, Hu F, Sun T, et al. Enhancement of glutamate uptake mediates the neuro protection exerted by activating group II or ll metabotropic glutamate reeptors on astrocytes [J]. J Neurochem, 2005: 92: 948-61
12 Gegelashvili G, Robinson MB, Trotti D. Regulation of glutamate transporters in health and disease [J]. Prog Brain Res2001: 132: 267-86
13 Sattler R, Xiong Z, Lu WY. Distinct roles of synaptic and extransynaptic NMDA receptors in excitotoxicity [J]. J Neurosci0000: 20: 22-33
14 Anderson CM, Swanson RA.Astrocyte glutamate transporterof properties, regulation, and physiological functions. J Glia. 2000: 32: 1-14
15 Danbolt NC. Glutamate uptakel[J]. Prog Neurobiol, 2001; 65: 1-15
16 姚红红,张芸,何海蓉,丁建花,李白告.胡刚. MPP⁺ 和6–羟基多巴胶对C6胶质瘤细胞摄取谷氨酸的影响[J],中国临床药理学与治疗学,2002;7:481 4
17 Davis KE, Straff D, Weinstein EA, Bannemman PG, Correale DM, Rothstein JD, et al. Multiple signaling pathways regulatecell surface expression and activity of the excitatory amino aridcarrier subtype of Glu transporter in C6 gliomal[J]. J Neurosci, 1998: 18: 2475-85
18 Golembiowska K, Konieczny J, Ossowska K, Wolfarth S. Therole of striatal metabotropic glutamate receptors in degenerationof dopamine neurons: review articlel[J]. Amino Acids, 2002; 199-205
19 Aronica E, Gorter JA, Ijlst-Keizers H, Rozemuller A J, Yankaya B, Leenstra S, Troost D. Expression and functionalmole of MGLUR3 and MGLUR5 in human astroeytes and gliomacells opposite regulation of glutamate transporter proteins[J]. Eur J Neurosci, 2003: 17: 210-18
20 Hazell AS, Pannunzio P. Rama Rao KV, Pow DV, RamhaldiA. Thiamine deficieney results in downregulation of the GLAST glutamnate transporter in cultured astrocytes [J]. Glia, 2003;43: 175-84
21 Malent MJ, Conn PJ. Glutamate receptors and Par-kinson disease: opportunities for intervention [J]. Drugs Aging, 2003; 20: 377-97

[1]	ZOU Jing, YAO Hong-Hong, HU Gang. Agonists of group II and III metabotropic glutamate receptors reverse LPS-induced glutamate uptake inhibition in C6 glioma cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(6): 626-629.
[2]	WANG Fang, YAO Hong-Hong, HU Gang. Group Ⅱ and Ⅲ metabotropic glutamate receptors agonists reverse 1-methyl-4-phenylpyridinium-induced glutamate uptake inhibition [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(5): 485-489.
[3]	MENG Chang-Hong, DING Jian-Hua, HU Gang. Lack effect of metabotropic glutamate receptors on neurotoxicity of PC12 cells induced by 6-OHDA1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(3): 269-272.
[4]	YAO Hong-Hong, ZHANG Yun, HE Hai-Rong, DING Jian-Hua, LI Hao, HU Gang. Effects of 1-methy-4-phenylpyridinium and 6-hydroxydopamine on the glutamate uptake into cultured C6 glioma cells¹ [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(6): 481-484.
[5]	FANG Fang, CHEN Xiao-Chun, ZHU Yuan-Gui. Possible mechanism of mitochondria on anti-apoptotic effect of ginsenoside Rg1 on MPP⁺-induced cellular apoptosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(5): 412-416.